Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 8, No 1 (2015) PHARMACOEPIDEMIOLOGICAL EVALUATION OF HEPATOTROPIC THERAPY IN REAL CLINICAL PRACTICE Abstract  similar documents
D. V. Blinov, U. V. Zimovina, T. I. Ushakova
"... and methods. 2450 patients were included in 98 sites. Non-interventional on therapeutic strategy study ..."
 
Vol 8, No 3 (2015) NON-ALCOHOLIC FATTY LIVER DISEASE OUTCOMES FUNNEL Abstract  similar documents
D. V. Blinov
"... prevalence of NAFLD within the GP-s patient flow (27%). These findings encourage to conduct a larger sample ..."
 
Vol 5, No 1 (2012) PHARMACOECONOMIC EVALUATION OF THE PROPHYLAXIS OF POSTSURGICAL INFECTIOUS INFLAMMATORY COMPLICATIONS OF COMBINED ANTIBIOTIC DRUGS AND CORTICOSTEROIDS IN OPHTHALMIC PRACTICE IN RUSSIAN FEDERATION Abstract  similar documents
V. G. Serpik, R. I. Yagudina
"... signs absence by 1% of patients at 14 day after operation.   ..."
 
Vol 8, No 2 (2015) REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS Abstract  similar documents
Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev
"... , risk management, and international rare diseases patient registries could be used to solve ..."
 
Vol 11, No 3 (2018) Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus Abstract  similar documents
A. G. Tolkushin, N. L. Pogudina
"... of systemic lupus erythematosus (SLe) in patients with high SLe activity, the presence of anti-DNA, a low ..."
 
Vol 12, No 4 (2019) Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer Abstract  similar documents
N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov
"... for the three-year period of 2020-2022. All patients who can be treated with palbociclib or ribociclib were ..."
 
Vol 10, No 4 (2017) PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... in patients with hemophilia A in the Russian Federation and propose the ways of optimizing this area ..."
 
Vol 6, No 2 (2013) FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS Abstract  similar documents
A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure
"... . Demographic, biochemical etc. patient parameters were used as input parameters. Glucose lowering drug ..."
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
"... to 6FAC. Use of 6DAC instead of 6FAC allows to reduce the number of patients with local relapse ..."
 
Vol 8, No 1 (2015) PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION Abstract  similar documents
M. V. Avxentyeva, N. A. Avxentyev, M. Yu. Frolov, E. V. Derkach
"... program of drug provision for patients suffering from 7 certain diseases and health states including organ ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... ) new practice where lenvatinib is used in 6.25% patients. Costs of drugs, visits to oncologist ..."
 
Vol 10, No 2 (2017) PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA Abstract  similar documents
M. Yu. Frolov, O. V. Shatalova
"... The aim of the study is to assess the economic feasibility of using pomalidomide in patients ..."
 
Vol 10, No 2 (2017) COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA Abstract  similar documents
N. L. Pogudina, E. G. Kosolapov, F. S. Kochenkov, A. V. Karaulov, N. L. Bondarenko, D. V. Blinov
"... using vilanterol / fluticasone furoate and budesonide / formoterol are 29,276 and 40,447 RUR per patient ..."
 
Vol 11, No 1 (2018) Presepsin as a sepsis biomarker Abstract  similar documents
K. A. Trunova
"... and severely burned patients. However, presepsin was not confirmed  as a marker of the disease severity ..."
 
Vol 11, No 2 (2018) Clinical and economic efficiency of the loop ileostomy closure by various methods Abstract  similar documents
A. V. Veselov, S. I. Achkasov, O. I. Sushkov, A. I. Moskalev, I. S. Lantsov
"... and methods. The study included 327 patients randomized into 3 groups. in group 1, the closure of an ileostomy ..."
 
Vol 6, No 1 (2013) PHARMACOECONOMIC STUDY OF SKIN TESTS IN THE DIAGNOSTICS OF TUBERCULOSIS INFECTION Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
"... were considered. Finally, total direct costs for the diagnostics one patient with active tuberculosis ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment Abstract  similar documents
A. U. Kulikov, V. V. Babiy
"... it patients use the glucose meters. However, there are some technique differences between meters that could ..."
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION Abstract  similar documents
A. Yu. Kulikov, I. Yu. Zinchuk
"... while preserving the patient's life. ..."
 
Vol 7, No 3 (2014) ECONOMIC JUSTIFICATION FOR TELEHEALTH TECHNOLOGY USE FOR PREVENTIVE MEDICAL EXAMINATION OF THE POPULATION IN REMOTE REGIONS Abstract  similar documents
D. V. Fedyaev, V. K. Fedyaeva, V. V. Omelyanovsky
"... of carrying out medical examination of patients with application of telemedical technologies and without ..."
 
Vol 6, No 4 (2013) Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа Abstract  similar documents
A. Yu. Kulikov, I. V. Novikov
"... in for patients with type 2 diabetes in condition of the Russian health care system. Total medical expenses ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... ) Eltrombopag and Romiplostim has been performed in patients with chronic idiopathic thrombocytopenic purpura ..."
 
Vol 10, No 2 (2017) COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov
"... (a difference of 24%). The average direct medical costs were 32,753 and 41,333 rubles per patient per year ..."
 
Vol 11, No 1 (2018) Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"... ). Based on a retrospective study of patients’ medical records, we selected the  parameters to be used ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"... analysis of these treatments, we used a number of indices derived from our retrospective study of patients ..."
 
Vol 12, No 3 (2019) Availability and Pharmacoeconomics of Insulin Therapy in Countries with the Largest Number of Diabetics Abstract  PDF (Eng)  similar documents
S. V. Ponomarenko
"... it in countries with the largest number of patients with diabetes. It was also aimed to assess the medical, social ..."
 
Vol 12, No 2 (2019) Recent changes in the pharmacovigilance system in the Russian Federation and the EAEU Abstract  similar documents
G. N. Gildeeva, A. V. Belostotsky
"... that of Roszdravnadzor, the discrepancy between the Patients information leaflet (“Instruction for medical use ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER Abstract  similar documents
A. U. Kulikov
"... of erlotinib as the 2nd line therapy of patients with local or metastatic NSCLC is more preferable than ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation Abstract  similar documents
A. Yu. Kulikov, L. A. Komarov
"... of approaches to treatment policy of this group of patients. We performed cost-effectiveness analysis ..."
 
Vol 7, No 3 (2014) PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA Abstract  similar documents
A. V. Pavlysh, A. S. Kolbin, A. R. Kasimova
"... of hospitalization (case reports) of 214 colorectal cancer patients treated with oxaliplatin at the St. Petersburg ..."
 
Vol 6, No 3 (2013) THE ANALYSIS OF THE MARKET OF PHARMACEUTICALS FOR DYSMENORRHEA TREATMENT Abstract  similar documents
N. Yu. Cherkasova, A. V. Fomina, O. V. Filippova
"... of sales whereas not only patients with dysmenorrhea provide the market requirements. Despite ..."
 
Vol 10, No 1 (2017) THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES Abstract  similar documents
N. Z. Musina, V. K. Fedyaeva
"... calculating methods, as well as the absence of uniform tariffs for assessing the medical status of the patient ..."
 
Vol 11, No 3 (2018) Use of medications in children hospitalized with community-acquired pneumonia Abstract  similar documents
D. D. Siukaeva, I. A. Narkevich, V. N. Timchenko, O. D. Nemyatyh, N. A. Maslova
"... with that, 45.70% of  patients had concomitant diseases; among those, acute respiratory infections of the upper ..."
 
Vol 12, No 2 (2019) Health technology assessment and reimbursement of pharmaceuticals in Italy Abstract  similar documents
F. V. Gorkavenko, V. V. Omelyanovskiy, T. P. Bezdenezhnykh, G. R. Khachatryan
"... such innovative approaches as the patient access schemes, early HTA and horizon scanning. ..."
 
Vol 12, No 4 (2019) The health technology assessment system in Australia Abstract  similar documents
V. V. Omelyanovskiy, E. S. Saybel, T. P. Bezdenezhnykh, G. R. Khachatryan
"... In Australia, the federal government is in charge of providing the health care to patients ..."
 
Vol 11, No 4 (2018) Clinical and economic studies on pharmacotherapy of malignant neoplasms: the modeling approach Abstract  similar documents
A. G. Tolkushin, S. K. Zyryanov, N. L. Pogudina, M. V. Davydovskaya
"... (and subsequent orders) can be applied to incorporate additional patient’s condition after the first progression ..."
 
Vol 12, No 2 (2019) Concerning the “repression” of ω -3 polyunsaturated fatty acids by adepts of evidence-based medicine Abstract  similar documents
I. Yu. Torshin, O. A. Gromova, Zh. D. Kobalava
"... used clinically heterogeneous cohorts of patients. We then selected a subsample of 19 clinically ..."
 
Vol 12, No 1 (2019) Individual cost accounting in the management of medical organizations Abstract  similar documents
I. A. Zheleznyakova, L. A. Kovaleva, T. A. Khelisupali
"... patient, considering the diagnosis, method of treatment, age and other classification signs, including ..."
 
Vol 10, No 2 (2017) COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov
"... ) by the fixed combination of LAAC / LABA (vilantererol / umeclidinum bromide) in patients with severe ..."
 
Vol 12, No 2 (2019) New framework for the development of clinical guidelines in Russia Abstract  similar documents
D. V. Blinov, E. S. Akarachkova, A. S. Orlova, E. V. Kryukov, D. I. Korabelnikov
"... of the development of the CG, reference materials, algorithms for doctor’s actions, patient information, assessment ..."
 
Vol 8, No 4 (2015) THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA Abstract  similar documents
K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva
"... for NE development and number of patients “needed to treat” (NNT) to prevent 1 NE case derived from ..."
 
Vol 10, No 1 (2017) CLINICAL AND ECONOMIC EVALUATION OF ERIBULIN EFFECTIVENESS IN SOFT TISSUE SARCOMA: RESULTS OF META-ANALYSIS Abstract  similar documents
P. V. Мazin, I. V. Sheshunov, N. K. Mazina, E. M. Markova
"... . Results. The relative number of patients, who survived for 12 months and continued their treatment ..."
 
Vol 7, No 3 (2014) MODELI NG CLINICAL AND ECONOMIC OUTCOMES OF TESTING FOR LTBI WITH T-SPOT.TB IN IMMUNOCOMPROMISED CHILDREN Abstract  similar documents
V. I. Ignatyeva, M. V. Avxentyeva, V. V. Omelyanovsky, G. R. Khachatryan
"... of 100 patients if the test's sensivity and specificity were 100% and prevalence of LTBI was 20%. When ..."
 
101 - 142 of 142 Items << < 1 2 3 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)